EUVIMEDEUVIMED entdecken
Crossref

PKBOIN ‐12: A Bayesian Optimal Interval Phase I/ II Design Incorporating Pharmacokinetics Outcomes to Find the Optimal Biological Dose

Hao Sun iD, Jieqi Tu

Pharmaceutical Statistics · 2025

DOI: 10.1002/pst.2444 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2025. Verfasst von Hao Sun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Global Biometrics & Data Sciences, Bristol Myers Squibb, Lawrenceville, New Jersey, USA. Hauptthemen laut MEDLINE: Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Research Design, Pharmacokinetics. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapies and targeted therapies have gained popularity due to their promising therapeutic effects across multiple treatment areas. The focus of early phase dose‐finding clinical trials has shifted from finding the maximum tolerated dose (MTD) to identifying the optimal biological dose (OBD), which aims to balance the toxicity and efficacy outcomes, thus optimizing the risk–benefit trade‐off. These trials often collect multiple pharmacokinetics (PK) outcomes to assess drug exposure, which has shown correlations with toxicity and efficacy outcomes but has not been utilized in the current dose‐finding designs for OBD selection. Moreover, PK outcomes are usually available within days after initial treatment, much faster than toxicity and efficacy outcomes. To bridge this gap, we introduce the innovative model‐assisted PKBOIN‐12 design, which enhances BOIN12 by integrating PK information into both the dose‐finding algorithm and the final OBD determination process. We further extend PKBOIN‐12 to TITE‐PKBOIN‐12 to address the challenges of late‐onset toxicity and efficacy outcomes. Simulation results demonstrate that PKBOIN‐12 more effectively identifies the OBD and allocates a greater number of patients to it than BOIN12. Additionally, PKBOIN‐12 decreases the probability of selecting inefficacious doses as the OBD by excluding those with low drug exposure. Comprehensive simulation studies and sensitivity analysis confirm the robustness of both PKBOIN‐12 and TITE‐PKBOIN‐12 in various scenarios.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase I as TopicClinical Trials, Phase II as TopicResearch DesignPharmacokineticsHumansBayes TheoremMaximum Tolerated DoseDose-Response Relationship, DrugComputer SimulationAlgorithms

Stichwörter der Autor:innen

Bayesian optimal interval designmodel‐assisted dose‐finding designoptimal biological dosepharmacokineticsrisk–benefit trade‐off

Autor:innen und Institutionen

  • Global Biometrics & Data Sciences, Bristol Myers Squibb, Lawrenceville, New Jersey, USA.
  • Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois Chicago, Chicago, Illinois, USA.

ORCID-Profile: Hao Sun

Zitieren

APA

Sun, H., & Tu, J. (2025). PKBOIN ‐12: A Bayesian Optimal Interval Phase I/ II Design Incorporating Pharmacokinetics Outcomes to Find the Optimal Biological Dose. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2444

Vancouver

Sun H, Tu J. PKBOIN ‐12: A Bayesian Optimal Interval Phase I/ II Design Incorporating Pharmacokinetics Outcomes to Find the Optimal Biological Dose. Pharmaceutical Statistics. 2025. doi:10.1002/pst.2444

BibTeX
@article{Sun2025,
  author = {Sun, Hao and Tu, Jieqi},
  title = {PKBOIN ‐12: A Bayesian Optimal Interval Phase I/ II Design Incorporating Pharmacokinetics Outcomes to Find the Optimal Biological Dose},
  journal = {Pharmaceutical Statistics},
  year = {2025},
  doi = {10.1002/pst.2444}
}
Kostenlos starten →